Significant decrease of the pathological stage I rectal carcinoma in the era of neoadjuvant therapy —A matter of concern
Neoadjuvant treatment (nTx) for rectal cancer is commonly reserved for UICC stages II/III. Patients with stage I tumours (T1-2N0M0) are not candidates for nTx. The accuracy of treatment allocation depends on the precision of clinical staging, which is liable to understaging and overstaging. The study aimed at exploring changes in the proportion of stage pI patients with the introduction of nTx over a 26-year period.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Sigmar Stelzner, Erik Puffer, Joerg Zimmer, Dorothea Bleyl, Thomas Kittner, Matthias Kuhn, Christiane Jakob, Helmut Witzigmann, Soeren T. Mees Tags: Original Research Source Type: research